PMID- 34614111
OWN - NLM
STAT- MEDLINE
DCOM- 20211025
LR  - 20220629
IS  - 1980-5322 (Electronic)
IS  - 1807-5932 (Print)
IS  - 1807-5932 (Linking)
VI  - 76
DP  - 2021
TI  - Efficacy and safety of secukinumab in patients with psoriatic arthritis: A 
      meta-analysis of different dosing regimens.
PG  - e2820
LID - 10.6061/clinics/2021/e2820 [doi]
LID - e2820
AB  - The appropriate dosing regimens of secukinumab for psoriatic arthritis (PsA) are 
      not well defined. We performed a meta-analysis to evaluate the efficacy and 
      safety of different dosing regimens of secukinumab in the treatment of PsA. A 
      systematic search was conducted using major electronic databases to identify 
      relevant randomized controlled trials (RCTs) comparing secukinumab 300 mg versus 
      secukinumab 150 mg in patients with PsA. Meta-analysis was performed using Review 
      Manager software (version 5.3). Six studies with a total of 1141 patients were 
      included. At week 24, secukinumab 300 mg was associated with a higher American 
      College of Rheumatology 20% response (ACR 20), ACR 50, PASI 75 response rate, and 
      dactylitis resolution rate than secukinumab 150 mg, especially in the anti-TNF-IR 
      subgroup. At week 52, secukinumab 300 mg was associated with a higher psoriasis 
      area and severity index (PASI) 75 and PASI 90 response rate than secukinumab 150 
      mg. There was no significant difference between secukinumab 300 mg and 
      secukinumab 150 mg in the risk of any adverse events (AEs) and serious AEs at 
      either week 24 or week 52. Secukinumab 300 mg was significantly more effective 
      than 150 mg, especially for patients with PsA who have failed TNF therapy, and it 
      was well tolerated.
FAU - Zhang, Kai-Lin
AU  - Zhang KL
AUID- ORCID: 0000-0003-3601-8475
AD  - China Medical University - The Queen's University of Belfast Joint College, 
      Shenbei New District, Shenyang, Liaoning 110122, China.
FAU - Hou, Si-Yuan
AU  - Hou SY
AUID- ORCID: 0000-0002-7785-5387
AD  - Intensive Care Unit, The People's Hospital of Liaoning province, Shenhe District, 
      Shenyang, Liaoning 110016, China.
FAU - Wu, Dan
AU  - Wu D
AUID- ORCID: 0000-0002-1528-6860
AD  - Second Department of Rheumatology, Shengjing Hospital of China Medical 
      University, Tiexi District, Shenyang, Liaoning 110022, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20211001
PL  - United States
TA  - Clinics (Sao Paulo)
JT  - Clinics (Sao Paulo, Brazil)
JID - 101244734
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - DLG4EML025 (secukinumab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - *Arthritis, Psoriatic/drug therapy
MH  - Humans
MH  - *Psoriasis
MH  - Severity of Illness Index
MH  - Treatment Outcome
PMC - PMC8449858
COIS- No potential conflict of interest was reported.
EDAT- 2021/10/07 06:00
MHDA- 2021/10/26 06:00
PMCR- 2021/09/20
CRDT- 2021/10/06 17:31
PHST- 2021/02/05 00:00 [received]
PHST- 2021/05/21 00:00 [received]
PHST- 2021/10/06 17:31 [entrez]
PHST- 2021/10/07 06:00 [pubmed]
PHST- 2021/10/26 06:00 [medline]
PHST- 2021/09/20 00:00 [pmc-release]
AID - S1807-5932(22)00167-3 [pii]
AID - cln_76p1 [pii]
AID - 10.6061/clinics/2021/e2820 [doi]
PST - epublish
SO  - Clinics (Sao Paulo). 2021 Oct 1;76:e2820. doi: 10.6061/clinics/2021/e2820. 
      eCollection 2021.